Wuyts A, Van Osselaer N, Haelens A, Samson I, Herdewijn P, Ben-Baruch A, Oppenheim J J, Proost P, Van Damme J
Laboratory of Molecular Immunology, Rega Institute for Medical Research, University of Leuven, Belgium.
Biochemistry. 1997 Mar 4;36(9):2716-23. doi: 10.1021/bi961999z.
Human granulocyte chemotactic protein 2 (GCP-2) has originally been isolated from cytokine-stimulated osteosarcoma cells as a chemokine coproduced in minute amounts together with interleukin 8. Human GCP-2 (75 residues) was synthesized on a 0.25-mmol scale using Fmoc chemistry. After disulfide bridge formation and purification, monomeric GCP-2 was recovered as a 6-kDa protein; the pure synthetic protein showed a molecular mass of 8076 Da as determined by matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS). The exact amino acid sequence of synthetic GCP-2 was confirmed by Edman degradation. Synthetic GCP-2 was an equally active (minimal effective concentration of 1-3 nM) chemoattractant for neutrophilic granulocytes as was natural 75-residue GCP-2. At concentrations up to 30 nM, synthetic GCP-2 did not stimulate eosinophil, monocyte, or lymphocyte chemotaxis. GCP-2 induced a dose-dependent increase in [Ca2+]i in neutrophils, 1 nM being the minimal effective concentration. The GCP-2-induced [Ca2+]i increase was completely prevented by pertussis toxin. Prestimulation of neutrophils with equimolar concentrations of purified natural IL-8, GROalpha, GROgamma and ENA-78 abolished the [Ca2+]i increase in response to 1 nM GCP-2. Alternatively, the [Ca2+]i rise induced by these CXC chemokines was inhibited by pretreatment of neutrophils with GCP-2. GCP-2 stimulated [Ca2+]i increases in CXCR1- and CXCR2-transfected cells, demonstrating that GCP-2 binds to both IL-8 receptors. Intradermal injection of synthetic GCP-2 resulted in a dose-dependent neutrophil accumulation and plasma extravasation in rabbit skin. To provoke this skin reaction, GCP-2 (10 pmol/site) was nearly as effective as IL-8, indicating that it is an important complementary mediator of the inflammatory response.
人粒细胞趋化蛋白2(GCP-2)最初是从细胞因子刺激的骨肉瘤细胞中分离出来的,是一种与白细胞介素8一起微量共产生的趋化因子。使用Fmoc化学方法在0.25 mmol规模上合成了人GCP-2(75个残基)。在形成二硫键并纯化后,单体GCP-2作为一种6 kDa的蛋白质被回收;通过基质辅助激光解吸/电离质谱(MALDI-MS)测定,纯合成蛋白的分子量为8076 Da。通过埃德曼降解法确认了合成GCP-2的确切氨基酸序列。合成GCP-2对嗜中性粒细胞的趋化活性与天然75个残基的GCP-2相同(最小有效浓度为1-3 nM)。在浓度高达30 nM时,合成GCP-2不会刺激嗜酸性粒细胞、单核细胞或淋巴细胞的趋化作用。GCP-2在嗜中性粒细胞中诱导[Ca2+]i呈剂量依赖性增加,1 nM为最小有效浓度。百日咳毒素可完全阻止GCP-2诱导的[Ca2+]i增加。用等摩尔浓度的纯化天然IL-8、GROα、GROγ和ENA-78对嗜中性粒细胞进行预刺激,可消除对1 nM GCP-2的[Ca2+]i增加反应。或者,这些CXC趋化因子诱导的[Ca2+]i升高可通过用GCP-2预处理嗜中性粒细胞来抑制。GCP-2刺激CXCR1和CXCR2转染细胞中的[Ca2+]i增加,表明GCP-2与两种IL-8受体结合。皮内注射合成GCP-2会导致兔皮肤中嗜中性粒细胞聚集和血浆外渗呈剂量依赖性。为引发这种皮肤反应,GCP-2(10 pmol/部位)的效果几乎与IL-8相同,表明它是炎症反应的重要补充介质。